Biogen Idec’s Long-acting Agents to Have Major Impact on Hemophilia Treatment Market, says the new Study on ASDReports

Wednesday 12 November 2014, Amsterdam

The hemophilia treatment landscape is to undergo a radical shift away from established short-acting therapies, beginning with the launch of Biogen Idec’s long-acting rFVIII and rFIX products this year, according to the new report on ASDReports.

The company’s latest report* also states that the patient shares of currently marketed short-acting recombinant products will erode considerably by 2022 across seven major markets (the US, France, Germany, Italy, Spain, the UK and Japan). Brooke Baker, Ph.D., GlobalData’s Senior Analyst covering Oncology and Hematology, says: “Biogen Idec’s new treatments have the potential to reduce the number of weekly prophylactic infusions and greatly improve patients’ convenience and quality of life. “By pricing its long-acting agents, namely Eloctate and Alprolix, in line with the established short-acting recombinant factors, Biogen Idec aims to incentivize patients to switch from their previous therapies.” The report forecasts that peak-year US sales for Eloctate and Alprolix will reach $786 million and $349 million by 2022, respectively. Another key factor behind Biogen Idec’s anticipated success will be its treatments’ first-to-market position among therapies of the same class, as it seeks to take a share of the market from established hemophilia players, such as Baxter, Novo Nordisk, Bayer and CSL Behring. Baker explains: “Eloctate and Alprolix launched in the US this year, ahead of their competitors in the hemophilia A and B markets, respectively. “As physicians view these and other emerging long-acting pipeline drugs as offering equivalent levels of clinical benefit, with few distinguishing attributes to influence patient preference, time-to-market and pricing will be pivotal in determining product uptake.” 

 PharmaPoint: Hemophilia A and B - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update
This report provides annualized hemophilia A and B therapeutics market revenue, annual cost of therapy and treatment usage pattern data by patient segment forecast from 2012 to 2022 across seven major markets (the US, France, Germany, Italy, Spain, the UK and Japan). Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and pipeline analysis. This report was built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis conducted by the report’s team of industry experts.